Phenotypic associations of genetic susceptibility loci in systemic lupus erythematosus
Objective: Systemic lupus erythematosus is a clinically heterogeneous autoimmune disease. A number of genetic loci that increase lupus susceptibility have been established. This study examines if these genetic loci also contribute to the clinical heterogeneity in lupus. Materials and methods: 4001 E...
- Autores:
- Tipo de recurso:
- Fecha de publicación:
- 2011
- Institución:
- Universidad del Rosario
- Repositorio:
- Repositorio EdocUR - U. Rosario
- Idioma:
- eng
- OAI Identifier:
- oai:repository.urosario.edu.co:10336/22400
- Acceso en línea:
- https://doi.org/10.1136/ard.2011.154104
https://repository.urosario.edu.co/handle/10336/22400
- Palabra clave:
- CD11b antigen
Cytotoxic T lymphocyte antigen 4
Fc receptor iia
Interleukin 21
Intermedin
Intermedin 5
Methyl cpg binding protein 2
Non receptor protein tyrosine phosphatase 22
OX40 ligand
Programmed death 1 receptor
STAT4 protein
Unclassified drug
Adult
African American
Article
Asian
Discoid lupus erythematosus
Ethnic group
European
Female
Gene frequency
Gene locus
Genetic predisposition
Genetic susceptibility
Genotype
Hematologic disease
Hispanic
Human
Inflammation
Kidney disease
Major clinical study
Male
Mouth ulcer
Neurologic disease
Onset age
Phenotype
Photosensitivity
Priority journal
Rash
Single nucleotide polymorphism
Systemic lupus erythematosus
Adult
African Americans
Asian Continental Ancestry Group
European Continental Ancestry Group
Female
Genetic Loci
Genetic Predisposition to Disease
Genotype
Humans
Lupus Nephritis
Male
Middle Aged
Oral Ulcer
Phenotype
Young Adult
Systemic
Single Nucleotide
Discoid
Lupus Erythematosus
Lupus Erythematosus
Polymorphism
- Rights
- License
- Abierto (Texto Completo)
Summary: | Objective: Systemic lupus erythematosus is a clinically heterogeneous autoimmune disease. A number of genetic loci that increase lupus susceptibility have been established. This study examines if these genetic loci also contribute to the clinical heterogeneity in lupus. Materials and methods: 4001 European-derived, 547 Hispanic, 1590 African-American and 1191 Asian lupus patients were genotyped for 16 confirmed lupus susceptibility loci. Ancestry informative markers were genotyped to calculate and adjust for admixture. The association between the risk allele in each locus was determined and compared in patients with and without the various clinical manifestations included in the ACR criteria. Results: Renal disorder was significantly correlated with the lupus risk allele in ITGAM (p=5.0 × 10-6, OR 1.25, 95% CI 1.12 to 1.35) and in TNFSF4 (p=0.0013, OR 1.14, 95% CI 1.07 to 1.25). Other significant findings include the association between risk alleles in FCGR2A and malar rash (p=0.0031, OR 1.11, 95% CI 1.17 to 1.33), ITGAM and discoid rash (p=0.0020, OR 1.20, 95% CI 1.06 to 1.33), STAT4 and protection from oral ulcers (p=0.0027, OR 0.89, 95% CI 0.83 to 0.96) and IL21 and haematological disorder (p=0.0027, OR 1.13, 95% CI 1.04 to 1.22). All these associations are significant with a false discovery rate of and lt;0.05 and pass the significance threshold using Bonferroni correction for multiple testing. Conclusion: Significant associations were found between lupus clinical manifestations and the FCGR2A, ITGAM, STAT4, TNSF4 and IL21 genes. The findings suggest that genetic profiling might be a useful tool to predict disease manifestations in lupus patients in the future. |
---|